Transient Dyschromatopsia, Static Form Agnosia, and Prosopagnosia Observed in a Patient with Anti-NMDA Receptor Encephalitis

Table 1

Laboratory data.

WBC	16700/μL	(3500–9700)	Influenza A	-
RBC	490 × 10^4/μL	(376–516 × 10^4)	Influenza B	-
Plt	28.7 × 10^4/μL	(14.0–37.9 ×10^4)	ANA	<40	(<79)
AST	12 IU/L	(8–38)	CEA/CLIA	1.1	(0.0–5.0)
ALT	10 IU/L	(4–44)	CA19–9	<=1.0	(0.0–37.0)
BUN	4.2 mg/dL	(8.0–20.0)	CA125	13.4	(0.0–35.0)
Cr	0.55 mg/dL	(0.47–0.79)	NSE/RIA	14.8	(0.1–16.3)
CPK	109 IU/L	(43–165)	CA602	10	(0–63)
UA	2.2 mg/dL	(2.7–7.0)	CSF
Na	142 mEq/L	(135–145)	cell count	185/mm^3	(0–15/mm^3)
K	4.3 mEq/L	(3.5–5.0)	mono	168/mm^3
Cl	105 mEq/L	(98–108)	poly	13/mm^3
Glucose	105 mg/dL	(70–109)	protein	46 mg/dL	(15–45)
CRP	0.48	(0.00–0.30)	glucose	61 mg/dL	(50–75)
TSH	0.39μIU/ml	(0.40–4.00)	HSV-PCR	-
FT3	2.33 pg/ml	(1.71–3.71)
FT4	1.19 ng/ml	(0.70–1.48)
			Serum Anti-NMDAR antibodies	1:800	2 months after admission
				1:3200	4 months after admission

(), Normal range; Anti-NMDAR antibodies, Anti-N-methyl-D-aspartate receptor antibodies.